The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
An overview of clinical and commercial impact of drug delivery systems
Open accessAbstract
Drug delivery systems are widely researched and developed to improve the delivery of pharmaceutical compounds and molecules. The last few decades have seen a marked growth of the field fueled by increased number of researchers, research funding, venture capital and the number of start-ups. Collectively, the growth has led to novel systems that make use of micro/nano-particles, transdermal patches, inhalers, drug reservoir implants and antibody-drug conjugates. While the increased research activity is clearly an indication of proliferation of the field, clinical and commercial translation of early-stage research ideas is critically important for future growth and interest in the field. Here, we will highlight some of the examples of novel drug delivery systems that have undergone such translation. Specifically, we will discuss the developments, advantages, limitations and lessons learned from: (i) microparticle-based depot formulations, (ii) nanoparticle-based cancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery, (vi) implants and (vii) antibody-drug conjugates. These systems have impacted treatment of many prevalent diseases including diabetes, cancer and cardiovascular diseases, among others. At the same time, these systems are integral and enabling components of products that collectively generate annual revenues exceeding US $100 billion. These examples provide strong evidence of the clinical and commercial impact of drug delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“Also, as a nanoparticle, Doxil® can target certain tumors via the enhanced permeability and retention (EPR) effect which allows small particles (~100 nm) to accumulate in the leaky outer vasculature surrounding tumors [28].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 2×
“It exhibits enhanced circulation, increased tumor persistence and improved half-life compared to free doxorubicin [19].”
BackgroundCancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · cited 1×
“Doxil® is a liposomal formulation of doxorubicin and was approved by the FDA for the treatment of AIDS-related Kaposi’s sarcoma in 1995 and for recurrent ovarian cancer in 1998 [21].”
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Prausnitz, M. R., & Langer, R. (2008) · Nature Biotechnology · doi:10.1038/nbt.1504 · Cited by 3,517
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Cited by
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Self-citationAlkilani, A., McCrudden, M. T., & Donnelly, R. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7040438 · Cited by 1,147
Emerging Frontiers in Drug Delivery
Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 975
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Polymer-Based Hydrogels Applied in Drug Delivery: An Overview
Thang, N. H., Chien, T. B., & Cuong, D. X. (2023) · Gels · doi:10.3390/gels9070523 · Cited by 812
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
Non-invasive delivery strategies for biologics
Anselmo, A. C., Gokarn, Y., & Mitragotri, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.183 · Cited by 665
Self-citationWen, H., Jung, H., & Li, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9814-9 · Cited by 574
A Review of Clinical Translation of Inorganic Nanoparticles
Anselmo, A. C., & Mitragotri, S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9780-2 · Cited by 509
Self-citationThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation
Park, K., Skidmore, S., Hadar, J., Garner, J., Park, H., Otte, A., Soh, B. K., Yoon, G., Yu, D., Yun, Y., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.003 · Cited by 404
Villa, C. H., Anselmo, A. C., Mitragotri, S., & Muzykantov, V. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.007 · Cited by 397
Self-citationStewart, S. A., Domínguez-Robles, J., Donnelly, R. F., & Larrañeta, E. (2018) · Polymers · doi:10.3390/polym10121379 · Cited by 390
Impact of particle elasticity on particle-based drug delivery systems
Anselmo, A. C., & Mitragotri, S. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.007 · Cited by 385
Self-citationControl of polymeric nanoparticle size to improve therapeutic delivery
Hickey, J. W., Santos, J. L., Williford, J.-M., & Mao, H.-Q. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.006 · Cited by 379
Drug delivery systems for programmed and on-demand release
Davoodi, P., Lee, L. Y., Xu, Q., Sunil, V., Sun, Y., Soh, S., & Wang, C.-H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.002 · Cited by 353
Anselmo, A. C., Modery-Pawlowski, C. L., Menegatti, S., Kumar, S., Vogus, D. R., Tian, L. L., Chen, M., Squires, T. M., Sen Gupta, A., & Mitragotri, S. (2014) · ACS Nano · doi:10.1021/nn503732m · Cited by 350
Self-citationReview of hybrid PLGA nanoparticles: Future of smart drug delivery and theranostics medicine
Ghitman, J., Biru, E. I., Stan, R., & Iovu, H. (2020) · Materials & Design · doi:10.1016/j.matdes.2020.108805 · Cited by 328
Protein aggregation and its impact on product quality
Roberts, C. J. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.08.001 · Cited by 316
A review of magnet systems for targeted drug delivery
Liu, Y.-L., Chen, D., Shang, P., & Yin, D.-C. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.031 · Cited by 298
Foundations of gastrointestinal-based drug delivery and future developments
Chu, J. N., & Traverso, G. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00539-w · Cited by 289
A Comprehensive Map of FDA-Approved Pharmaceutical Products
Zhong, H., Chan, G., Hu, Y., Hu, H., & Ouyang, D. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040263 · Cited by 288
Vlachopoulos, A., Karlioti, G., Balla, E., Daniilidis, V., Kalamas, T., Stefanidou, M., Bikiaris, N. D., Christodoulou, E., Koumentakou, I., Karavas, E., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020359 · Cited by 277
Nanocrystals: a perspective on translational research and clinical studies
Jarvis, M., Krishnan, V., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10122 · Cited by 162
Self-citationRuan, C., Liu, L., Lu, Y., Zhang, Y., He, X., Chen, X., Zhang, Y., Chen, Q., Guo, Q., Sun, T., et al. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.09.008 · Cited by 138
RetractedCreation of a long-acting nanoformulated dolutegravir
Sillman, B., Bade, A. N., Dash, P. K., Bhargavan, B., Kocher, T., Mathews, S., Su, H., Kanmogne, G. D., Poluektova, L. Y., Gorantla, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02885-x · Cited by 125
Metadata
- Authors
- Anselmo, A. C., & Mitragotri, S.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 190
- Pages
- 15-28
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2046627126
- Cited by
- 520
- References
- 117
- FWCI
- 19.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.